281 related articles for article (PubMed ID: 21621301)
1. [Hexaminolevulinate photodynamic diagnosis in non-muscle invasive bladder cancer: experience of the BLUE group].
Burgués JP; Conde G; Oliva J; Abascal JM; Iborra I; Puertas M; Ordoño F;
Actas Urol Esp; 2011 Sep; 35(8):439-45. PubMed ID: 21621301
[TBL] [Abstract][Full Text] [Related]
2. Oral 5-aminolevulinic acid in simultaneous photodynamic diagnosis of upper and lower urinary tract transitional cell carcinoma - a prospective audit.
Ahmad S; Aboumarzouk O; Somani B; Nabi G; Kata SG
BJU Int; 2012 Dec; 110(11 Pt B):E596-600. PubMed ID: 22758907
[TBL] [Abstract][Full Text] [Related]
3. Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic Acid under visible and fluorescent light: results of a prospective, randomised, multicentre study.
Schumacher MC; Holmäng S; Davidsson T; Friedrich B; Pedersen J; Wiklund NP
Eur Urol; 2010 Feb; 57(2):293-9. PubMed ID: 19913351
[TBL] [Abstract][Full Text] [Related]
4. [Value of the photodynamic method in the diagnosis of superficial bladder tumors].
Lipiński MI; Jeromin LM
Wiad Lek; 2004; 57 Suppl 1():192-5. PubMed ID: 15884237
[TBL] [Abstract][Full Text] [Related]
5. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study.
Fradet Y; Grossman HB; Gomella L; Lerner S; Cookson M; Albala D; Droller MJ;
J Urol; 2007 Jul; 178(1):68-73; discussion 73. PubMed ID: 17499291
[TBL] [Abstract][Full Text] [Related]
6. [Fluorescence diagnosis in patients with non-muscle invasive bladder cancer: results of a metaanalysis].
Kausch I; Sommerauer M; Montorsi F; Stenzl A; Jacqmin D; Jichlinski P; Jocham D; Ziegler A; Vonthein R
Aktuelle Urol; 2010 May; 41(3):171-7. PubMed ID: 20486035
[TBL] [Abstract][Full Text] [Related]
7. Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors.
Burger M; Stief CG; Zaak D; Stenzl A; Wieland WF; Jocham D; Otto W; Denzinger S
Urology; 2009 Dec; 74(6):1282-6. PubMed ID: 19819538
[TBL] [Abstract][Full Text] [Related]
8. Hexylaminolaevulinate 'blue light' fluorescence cystoscopy in the investigation of clinically unconfirmed positive urine cytology.
Ray ER; Chatterton K; Khan MS; Thomas K; Chandra A; O'Brien TS
BJU Int; 2009 May; 103(10):1363-7. PubMed ID: 19076151
[TBL] [Abstract][Full Text] [Related]
9. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data.
Burger M; Grossman HB; Droller M; Schmidbauer J; Hermann G; Drăgoescu O; Ray E; Fradet Y; Karl A; Burgués JP; Witjes JA; Stenzl A; Jichlinski P; Jocham D
Eur Urol; 2013 Nov; 64(5):846-54. PubMed ID: 23602406
[TBL] [Abstract][Full Text] [Related]
10. Outpatient diagnostic of bladder tumours in flexible cystoscopes: evaluation of fluorescence-guided flexible cystoscopy and bladder biopsies.
Hermann GG; Mogensen K; Toft BG; Glenthøj A; Pedersen HM
Scand J Urol Nephrol; 2012 Feb; 46(1):31-6. PubMed ID: 22150596
[TBL] [Abstract][Full Text] [Related]
11. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
Geavlete B; Multescu R; Georgescu D; Jecu M; Stanescu F; Geavlete P
BJU Int; 2012 Feb; 109(4):549-56. PubMed ID: 21711438
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of hexaminolevulinate fluorescence cystoscopy for the diagnosis of non-muscle-invasive bladder cancer in daily clinical practice: a Spanish multicentre observational study.
Palou J; Hernández C; Solsona E; Abascal R; Burgués JP; Rioja C; Cabrera JA; Gutiérrez C; Rodríguez O; Iborra I; Herranz F; Abascal JM; Conde G; Oliva J
BJU Int; 2015 Jul; 116(1):37-43. PubMed ID: 25496450
[TBL] [Abstract][Full Text] [Related]
13. Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis.
Burger M; Zaak D; Stief CG; Filbeck T; Wieland WF; Roessler W; Denzinger S
Eur Urol; 2007 Jul; 52(1):142-7. PubMed ID: 17267099
[TBL] [Abstract][Full Text] [Related]
14. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.
O'Brien T; Ray E; Chatterton K; Khan MS; Chandra A; Thomas K
BJU Int; 2013 Dec; 112(8):1096-104. PubMed ID: 24053153
[TBL] [Abstract][Full Text] [Related]
15. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study.
Jocham D; Witjes F; Wagner S; Zeylemaker B; van Moorselaar J; Grimm MO; Muschter R; Popken G; König F; Knüchel R; Kurth KH
J Urol; 2005 Sep; 174(3):862-6; discussion 866. PubMed ID: 16093971
[TBL] [Abstract][Full Text] [Related]
16. Seven years' experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder.
Hungerhuber E; Stepp H; Kriegmair M; Stief C; Hofstetter A; Hartmann A; Knuechel R; Karl A; Tritschler S; Zaak D
Urology; 2007 Feb; 69(2):260-4. PubMed ID: 17320660
[TBL] [Abstract][Full Text] [Related]
17. The clinical trial on the safety and effectiveness of the photodynamic diagnosis of non-muscle-invasive bladder cancer using fluorescent light-guided cystoscopy after oral administration of 5-aminolevulinic acid (5-ALA).
Inoue K; Matsuyama H; Fujimoto K; Hirao Y; Watanabe H; Ozono S; Oyama M; Ueno M; Sugimura Y; Shiina H; Mimata H; Azuma H; Nagase Y; Matsubara A; Ito YM; Shuin T
Photodiagnosis Photodyn Ther; 2016 Mar; 13():91-96. PubMed ID: 26751700
[TBL] [Abstract][Full Text] [Related]
18. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer.
Grossman HB; Gomella L; Fradet Y; Morales A; Presti J; Ritenour C; Nseyo U; Droller MJ;
J Urol; 2007 Jul; 178(1):62-7. PubMed ID: 17499283
[TBL] [Abstract][Full Text] [Related]
19. Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study.
Hermann GG; Mogensen K; Carlsson S; Marcussen N; Duun S
BJU Int; 2011 Oct; 108(8 Pt 2):E297-303. PubMed ID: 21414125
[TBL] [Abstract][Full Text] [Related]
20. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy.
Schmidbauer J; Witjes F; Schmeller N; Donat R; Susani M; Marberger M;
J Urol; 2004 Jan; 171(1):135-8. PubMed ID: 14665861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
